Edmondson Frazor Titus III Buys Shares of Zai Lab Limited

Edmondson Frazor Titus III, the Chief Legal Officer of Zai Lab Limited, made a significant move by purchasing 14,600 shares of the company on June 25, 2026. This insider buy comes at a time when the company's stock is trading around $18 on the NasdaqGM.

Insider Buying and Selling at Zai Lab Limited

Edmondson Frazor Titus III acquired 14,600 shares, highlighting his confidence in the company's prospects. Additionally, on June 26, 2026, Du Ying, the Chairperson and CEO, sold 24,543 shares at $17.46 each, while Titus III and Chief Financial Officer Chen Yajing also sold smaller amounts at the same price.

Zai Lab Limited Stock Down 29.4%

Shares of Zai Lab Limited (NasdaqGM: ZLAB) traded near $18 on Tuesday. The company, with a market cap of approximately $2.03 billion, has a forward P/E ratio that isn't meaningful due to its lack of profitability. The stock's 52-week range is between $15.96 and $41.20, with a 50-day moving average of $19.52 and a 200-day moving average of $21.50. Zai Lab has a current ratio of 2.40 and a debt-to-equity ratio of 35.03.

Recent Earnings

Zai Lab Limited reported revenue of $453.28 million, with a revenue decline of 6.5%. The company posted a negative net margin of 39.3% and a return on equity of -24.2%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

Analysts continue to show optimism for Zai Lab Limited. On May 8, 2026, Citigroup maintained its "buy" rating with a price target of $44. JP Morgan also upheld its "buy" rating, setting a target of $32 on March 18, 2026. Overall, the consensus price target stands at approximately $33.30, with 12 analysts providing opinions.

About Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company based in Pudong, China, focused on developing and commercializing treatments for conditions in oncology, immunology, neuroscience, and infectious diseases. The company offers several commercial products for various medical conditions and collaborates with major pharmaceutical companies like Pfizer and Amgen. Founded in 2013, Zai Lab is led by CEO Dr. Ying Du and employs around 1,784 people.

Bottom Line

The insider purchase by Edmondson Frazor Titus III suggests a vote of confidence in Zai Lab Limited's future. Investors often watch such insider moves for potential insights into a company's prospects. While Zai Lab faces challenges with profitability, analyst confidence remains, as reflected in the maintained "buy" ratings and price targets. As always, it's important to remember that insider transactions are disclosed after the fact and may not reflect the current situation.